** Pfizer PFE.N on Tuesday beat Wall Street estimates for fourth-quarter profit driven by cost cuts and steadier COVID vaccine sales
** PFE has been looking to show investors steadier execution and growth after large swings related to its COVID-19 vaccine
OBESITY DATA IS 'LITMUS TEST' FOR PIPELINE
** BMO Capital Markets ("Outperform", PT: $38) says Pfizer continues to execute the plan outlined for investors in what is shaping up to be a manageable macro and political environment
** J.P Morgan ("Neutral", PT: $30) says that while it sees several assets in PFE's pipeline (particularly in oncology) that could make the story more interesting, further progress is necessary to change the narrative on shares
** Guggenheim Partners ("Buy", PT: $33) says data from Pfizer's experimental obesity drug, danuglipron, will be a "litmus test for the company's pipeline productivity"
** Leerink ("Market Perform," PT: $28) says "management is executing well and delivering results above expectations, but we await future pipeline developments"
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。